Blood pressure response index and acute kidney injury progression in heart failure patients: a retrospective cohort study from MIMIC-IV Authors: Baoxin Yan, Xianzhen Cai, Jiating Su, Jinhao Chen, Shuangshuang Tong, Junjun Ye, Weiwen Li, Ying Lin, Xiaojun Huang, Bin Xie, Jilin Li Published: 2025 ABSTRACT BackgroundIn heart failure (HF), acute kidney injury (AKI) is an independent risk factor of mortality, and severer stage of AKI is associated with poorer prognosis. Blood pressure response index (BPRI) reflects the cardiovascular response to vasoactive drugs which are commonly used to increase perfusion to the vital organs. We sought to investigate the association between BPRI and AKI progression in HF patients.MethodsThis was a retrospective cohort study collected the data from MIMIC-IV version 3.0. We collected the minimum value of BPRI within 24 hours of ICU admission (T0). The AKI progression was defined as an increase of at least one AKI stage within 48 hours after T0 (T1). The new incidence of AKI at T1 was also considered as AKI progression. The patients were divided into four distinct groups based on the quartiles of the BPRI.ResultsA total of 3147 patients with HF were included, of whom 1883 (59.8%) were male and a median age of 73.80 [64.50, 82.33] years. 1571 (49.9%) experienced AKI progression. The quartiles 1 group exhibited the lowest 90-day survival rate, especially in patients who developed AKI progression (all log-rank p < 0.001). Compared to the patients in quartiles 1, those in higher quartiles had a significantly lower risk of AKI progression (in full-adjusted model: quartiles 2 OR 0.94, 95% CI 0.77–1.17, p = 0.594; quartiles 3 OR 0.64, 95% CI 0.52–0.79, p < 0.001; quartiles 4 OR 0.70, 95% CI 0.56–0.87, p = 0.001). There was an asymmetric U-shaped relationship between BPRI and AKI progression, with a cutoff value of 12.0 (P-overall < 0.001, P-non-linear < 0.001). Similar results in stratified analyses based on the AKI situation (without AKI, AKI stage 1, AKI stage 2) at T0 were observed (compared to quartiles 1 group, the OR of other quartiles group were less than 1).ConclusionsWhen below the cut-off, a lower BPRI within the first 24 hours of ICU admission is associated with increased risk of AKI progression in the following 48 hours among HF patients, regardless of initial AKI situation.Supplementary informationThe online version contains supplementary material available at 10.1186/s12882-025-04668-1. Introduction Heart failure (HF) imposes a great burden on the global healthcare system [1, 2]. It is worth noting that comorbidity burden and non-CV mortality are increasing among HF patients [1], especially in those with concurrent kidney dysfunction [3]. HF is a complex clinical syndrome characterized by elevated intracardiac pressures and/or inadequate cardiac output at rest or during exercise, resulting from structural and/or functional abnormalities of the heart [4]. The heart and kidney have intricate and reciprocal interactions, such as hemodynamic alterations, dysregulation of the (neuro) hormonal axis, and mechanisms associated with cardiovascular diseases [3]. The failing heart is unable to generate adequate forward flow, leading to prerenal hypoperfusion, which is the conventional explanation for cardiorenal syndrome (CRS) [5]. Characterized by an abrupt decline in kidney function, acute kidney injury (AKI) is further divided into three stages according to its severity [6]. AKI frequently occurs in HF and is associated with higher risk of mortality. A meta-analysis reported that 33% of HF patients were combined with AKI, and their risk of hospital mortality was over three times higher than those without AKI [7]. The 1-year mortality was also nearly doubled [7]. Moreover, with the stage of AKI increases, the mortality rises in a stepwise manner in critically ill patients [8, 9]. Vasoactive drugs are used to increase perfusion in patients with low cardiac output and hypotension [4]. The vasoactive–inotropic score (VIS) is the most commonly used formula to standardize the dosages of different vasoactive drugs in cardiovascular diseases [10]. A previous study had found that a higher initial VIS or a significantly rising VIS was related to increase in-hospital mortality among cardiogenic shock or mixed shock patient [11]. Given the potential adverse effects of high-dose vasoactive drugs, it is recommended to use the lowest possible dose and for the shortest necessary duration [4, 12]. Combining mean arterial pressure (MAP) and VIS, the blood pressure response index (BPRI) assesses the cardiovascular responsiveness to vasoactive drugs rapidly and precisely [13]. As one of the key features of refractor shock [14], vascular hypo-responsiveness to vasopressors refers to the inability to increase arterial pressure despite high doses of vasoconstrictor agents [15]. Previous study found the sepsis patients with vascular hypo-responsiveness but normal cardiac function was associated with higher risk of AKI [16]. There are limited studies on cardiovascular responsiveness to vasoactive drugs, including vasopressors and inotropic agents, in patients with impaired cardiac function. Therefore, we aim to explore the association between BPRI and AKI progression in HF patients in this study. Additionally, we sought to investigate whether the initial degree of kidney impairment influences this association. Methods Data resource The data were collected from the Medical Information Mart for Intensive Care IV database (MIMIC-IV, version 3.0). This version of MIMIC-IV contains health-related data of more than 65,000 ICU patients admitted to the Beth Israel Deaconess Medical Center (BIDMC; Boston, MA, USA) from 2008 to 2022 [17]. The author (Baoxin Yan) has obtained a Collaborative Institutional Training Initiative (CITI) license (Record ID: 12,861,338) and necessary permission to use the database. The project received approval from the Institutional Review Board of both the Massachusetts Institute of Technology and Beth Israel Deaconess Medical Center, with patient privacy protected through strict safeguards of their identifying information. Study population In this retrospective cohort study, we enrolled ICU patients diagnosed with HF based on the Ninth and Tenth revisions of the International Classification of Diseases (ICD) codes. The exclusion criteria included: I. aged below 18-year-old; II. ICU stay duration less than 24 hours; III. admitted for neurological disorders, trauma, obstetric, or gynecological conditions; IV. not received at least one vasoactive drug (epinephrine, norepinephrine, phenylephrine, vasopressin, dopamine, dobutamine or milrinone) or lacked MAP data within the first 24 hours of ICU admission (T0); V. lacked AKI data; VI. with stage 3 AKI or need of renal replacement therapy (RRT) within T0, or diagnosed stage 5 chronic kidney disease (CKD). The study population was divided into four groups based on the quartiles of the BPRI (Fig. 1).Fig. 1Flow chart of patient selection Flow chart of patient selection Outcomes The primary outcome was AKI progression which was defined as an increase of at least one AKI stage between 24 hours to 72 hours of ICU admission (T1). Those diagnosed AKI within T1 but without AKI within T0 were also considered as AKI progression [18, 19]. The definitions of AKI and its stage determined by the increased level of creatine, decreased level of urine output and whether receipt RRT, which can be referenced in 2012 KDIGO AKI Guideline [6]. The secondary outcomes included the incidence of AKI stage 3, receipt of RRT, new arrhythmia (new-onset atrial fibrillation (AF), ventricular tachycardia, ventricular fibrillation, asystole) within 14 days after T0 (T2), mortality (hospital death, 90-day mortality), and hospital-related outcomes (length of hospital and ICU stay, rehospitalization within 90-day). New-onset AF was defined as AF that developed within T2 but not within T0, as identified through electrocardiographic monitoring. Data collection BPRI was calculated by dividing the minimum MAP by the maximum VIS per hour [13]. The minimum BPRI within T0 was recorded. VIS is calculated as follows [20]\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\begin{aligned} VIS{\text{ }} & = {\text{ }}norepinephrine\left( {\mu g/kg/min} \right){\text{ }} \times 100 \\ & + {\text{ }}epinephrine\left( {\mu g/kg/min} \right){\text{ }} \times 100 \\ &+ {\text{ }}phenylephrine\left( {g/kg/min} \right){\text{ }} \times 10 \\ & + {\text{ }}dopamine\left( {\mu g/kg/min} \right){\text{ }} \times 1 \\ &+ {\text{ }}dobutamine\left( {\mu g/kg/min} \right){\text{ }} \times 1 \\ &+ {\text{ }}milrinone\left( {\mu g/kg/min} \right){\text{ }} \times 1 \\ &+ {\text{ }}vasopressin\left( {U/kg/min} \right){\text{ }} \times 10,000 \\ \end{aligned} $$\end{document} We also collected data from the following seven categories: I. demographics: gender, age, BMI; II. vital signs: heart rate, blood pressure, fluid balance, etc.; III. laboratory tests: creatinine (Scr), albumin, N-terminal pro-brain natriuretic peptide (NT-proBNP), etc.; IV. comorbidities: diabetes, hypertension, acute myocardial infarction (AMI), etc.; V. disease severity scores: Charlson comorbidity index, acute physiology score (APS)score, systemic inflammatory response syndrome (SIRS), sequential organ failure assessment (SOFA) score, etc.; VI. treatments: respiratory support, intra-aortic balloon pump (IABP) application, advanced MCS application11 (including impella, tandemheart, venoarterial extracorporeal membrane oxygenation (ECMO), surgical implantable ventricular assist device); VII. medications: angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), loop diuretics, antibiotics, non-steroidal anti-inflammatory drugs (NSAID), etc. Notably, the data on vital signs, laboratory test, disease severity score, treatment, and medications were obtained within T0. The software PostgreSQL (version 13.7.1) and Navicat Premium (version 17) were used to extract the data. For the variables with missing rate less than 30%, multiple imputation approach (MICE R) was employed to interpolate missing values. The other variables were transformed into dummy variables, and only those with a missing rate of less than 80% were included in the models (Table S1). ALT, AST, total bilirubin, TNT, CK-MB, HbA1c, NT-proBNP contained 30–80% missing values, while triglyceride, HDL-C, LDL-C, cholesterol, CRP, ACR contained over 80% missing values. Statistical analysis The continuous variables were described using median (interquartile range (IQR)) or mean (standard deviation (SD)), and comparisons between groups were performed using the analysis of variance or Kruskal-Wallis test, as appropriate. The categorical variables were described as frequency (percentage (%)), and compared between groups using Fisher’s exact test or Pearson’s chi-square test. A two-sided p value less than 0.05 was considered statistically significant. Kaplan-Meier survival analysis was employed to estimate the incidence of 90-day mortality among groups based on the BPRI quartiles with the log-rank test to assess the differences among the survival curves. To assess the relationship of BPRI on AKI progression, logistic regression analysis was conducted. We controlled for various confounding factors by incorporating correction variables derived from previous research and statistical analyses. The possible risk factors with univariate logistic regression p value less than 0.05 were entered in the models after excluding covariates with significant collinearity. Additionally, based on the clinical relevance and the importance of risk factors for AKI in previous studies [21, 22], Scr, albumin, NT-proBNP, lactate, fluid balance, APS) score, blood transfusion, ACEI/ARB, NSAID, application of IABP and advanced MCS, CKD, hypertension, diabetes, shock, sepsis, and AMI were also included in the adjusted models regardless of their p values. Model 1 solely included BPRI, and model 2 further adjusted gender, age, race and BMI. Based on Model 2, Model 3 incorporated laboratory test results, fluid balance, and treatments, whereas Model 4 incorporated HF type, surgical status, complications. Results were reported as odds ratios (ORs) and respective 95% confidence intervals (CIs). To analyze the potential non-linear relationship, restricted cubic splines (RCS) analysis was conducted. In addition, we conducted a stratified analysis of initial AKI status within T0 (without AKI, AKI stage 1, AKI stage 2). To explore potential differences in subgroups, the subgroup analysis was conducted and adjusted by the model with lower AIC. The subgroup included gender, age (≤65 and > 65 years-old), BMI ( < 30 and ≥30 kg/m2), whether receipt cardiac surgery, HF classification (AHF, CHF, AECHF and not described), sepsis, shock, CKD, AMI, AF, hypertension, and DM. To assess the robustness of our main findings, we performed sensitivity analyses by repeating logistic regression analyses and RCS after excluding the patients: a) with missing NT-proBNP value or where NT-proBNP was less than 300 pg/mL; b) whose length of ICU stay less than 72 hours; c) who used vasoactive drugs less than 4 hours, respectively. Furthermore, considering that the hemodynamic profiles and treatment strategies of patients who had undergone cardiac surgery, those with sepsis, or those with AMI differ from those of general HF patients, we excluded these subgroups respectively and repeated logistic regression analyses. To preserve statistical power in sensitivity analyses following subgrouping or exclusion where the number of outcome events was reduced, we restricted covariate adjustment to only those variables identified as confounders in previous studies [21, 22]. Multicollinearity was assessed using variance inflation factor (VIF) analysis, with VIF values less than 5 considered indicative of acceptable collinearity. To estimate the independent association of BPRI with AKI progression, we adjusted for its constituent variables, MBP and VIS. Receiver-operating characteristic (ROC) curve analysis was performed to assess the predictive performance of BPRI, MBP, and VIS, with comparisons between area under the curve (AUC) conducted using the DeLong test. All the statistical analyses were executed using R software (version 4.4.1). Results Baseline characteristics A total of 3147 HF patients were included in this study, of whom 1883 (59.8%) were male and median age was 73.80 [64.50, 82.33] years. 517 (16.4%) patients presented acute heart failure (AHF) and 1076 (34.2%) presented acute exacerbation of chronic heart failure (AECHF) while 886 (28.2%) receipted cardiac surgery. 2041 (64.9%) patients occurred AKI within T0. The minimum BPRI was 4.77 [2.37, 9.37], while VIS was 12.01 [7.00, 23.01] and MAP was 61.00 [54.00, 69.00] mmHg at the time of the minimum BPRI. The patients were further divided into four distinct groups based on the quartiles of the BPRI (quartile Q1: 0.01–2.37; Q2: 2.37–4.77; Q3: 4.77–9.37; Q4: 9.37–91.97), with BPRI were 1.32 [0.79, 1.80], 3.48 [2.90, 4.08], 6.50 [5.63, 7.62], 13.80 [11.40, 20.66], respectively. Patients in Q1 group were characterized by lower BMI, higher illness severity scores, higher stage of AKI initially, and higher incidence of AHF, AECHF, AMI, peripheral vascular disease, pneumonia, liver disease, cancer, sepsis and shock. They received higher doses and a greater variety of vasoactive drugs, with norepinephrine, vasopressin, and milrinone being used more frequently. Further, more aggressive rehydration therapy and more frequent amiodarone use, blood transplantation, IABP and major MCS were also received. However, lower mean blood pressure (SBP, DBP and MBP), higher mean heart rate and less urine output within T0 were observed. In addition, this group demonstrated lower level of albumin, PH, PO2, oxygenation index, as well as higher level of Scr, BUN, WBC, lactate, ALT, AST, total bilirubin, potassium, glucose. Moreover, patients with value of TNT greater than 0.50 μg/L and CKMB greater than 10 IU/L were more common (all p < 0.05) (Table 1). Clinical outcomes 1571 (49.9%) patients occurred AKI progression and 585 (18.6%) patients developed AKI stage 3 within T1. Table S2 and S3 respectively compared the baseline characteristics between patients with and without AKI progression, and between those who developed AKI stage 3 and those who did not. 117 (3.7%) patients receipted of RRT, 516 (16.4%) patients occurred new atrial fibrillation within T2. It can be observed that Q1 group had higher incidence of AKI related outcomes, new arrythmia, mortality and hospital related outcomes compared with other groups (all p < 0.05). Therefore, we chosen Q1 group as the reference group (Table 2). We also compared the incidence of clinical outcomes between patient with or without AKI progression (Table S4). Among patients with AKI progression, 585 (37.2%) developed stage 3 AKI, and 109 (6.9%) received RRT within T2. They had higher hospital mortality and 90-day mortality than those without AKI progression (both p < 0.05).Table 1Baseline characteristics according to BPRI index quartilesVariablesOverallGroup divided by BPRIP valueQ1Q2Q3Q4General characteristicsMale, %1883 (59.8)465 (59.1)482 (61.2)462 (58.8)474 (60.2)0.741Age, years73.80 [64.50, 82.33]74.60 [64.89, 82.89]75.08 [66.23, 82.70]74.07 [64.80, 82.80]71.74 [62.63, 80.50] < 0.001Race, %0.196 White2239 (71.1)532 (67.6)562 (71.4)586 (74.6)559 (71.0) Black188 (6.0)51 (6.5)46 (5.8)36 (4.6)55 (7.0) Asian77 (2.4)24 (3.0)18 (2.3)16 (2.0)19 (2.4) Others643 (20.4)180 (22.9)161 (20.5)148 (18.8)154 (19.6)BMI, kg/m228.34 [24.42, 33.08]27.81 [24.03, 32.41]28.30 [24.35, 32.66]28.35 [24.69, 33.11]28.89 [24.84, 34.12]0.007Surgery, %886 (28.2)136 (17.3)236 (30.0)235 (29.9)279 (35.5) < 0.001Classification of HF, % < 0.001 AHF517 (16.4)172 (21.9)130 (16.5)109 (13.9)106 (13.5) CHF977 (31.0)188 (23.9)249 (31.6)264 (33.6)276 (35.1) AECHF1076 (34.2)304 (38.6)267 (33.9)271 (34.5)234 (29.7)Not described577 (18.3)123 (15.6)141 (17.9)142 (18.1)171 (21.7)Right heart failure, %25 (0.8)7 (0.9)6 (0.8)5 (0.6)7 (0.9)0.932BPRI (minimum of 24 h)4.77 [2.37, 9.37]1.32 [0.79, 1.80]3.48 [2.90, 4.08]6.50 [5.63, 7.62]13.80 [11.40, 20.66] < 0.001VIS (at the time of the minimum BPRI)12.01 [7.00, 23.01]40.05 [30.01, 56.40]17.97 [15.00, 20.03]10.00 [8.00, 10.02]5.00 [3.00, 5.00] < 0.001MBP (at the time of the minimum BPRI)61.00 [54.00, 69.00]56.00 [46.00, 64.00]60.00 [53.00, 67.00]63.00 [57.00, 69.00]66.00 [59.00, 74.00] < 0.001Charlson comorbidity index6.00 [5.00, 8.00]7.00 [5.00, 8.00]6.00 [5.00, 8.00]6.00 [5.00, 8.00]6.00 [5.00, 8.00] < 0.001APS 45.00 [34.00, 59.00]55.00 [43.50, 72.00]44.00 [35.00, 58.00]42.00 [32.00, 55.00]40.00 [31.00, 51.00] < 0.001SOFA score7.00 [5.00, 9.00]7.00 [5.00, 9.00]7.00 [5.00, 9.00]7.00 [5.00, 9.00]7.00 [5.00, 9.00]0.236SIRS3.00 [2.00, 3.00]3.00 [3.00, 4.00]3.00 [2.00, 3.00]3.00 [2.00, 3.00]3.00 [2.00, 3.00] < 0.001Situation of AKI within 24 h < 0.001No AKI1106 (35.1)219 (27.8)289 (36.7)297 (37.8)301 (38.2)Stage 1732 (23.3)176 (22.4)190 (24.1)165 (21.0)201 (25.5)Stage 21309 (41.6)392 (49.8)308 (39.1)324 (41.2)285 (36.2)Vasoactive drug and maximum dosage used within 24 hDopamine, %273 (8.7)80 (10.2)58 (7.4)53 (6.7)82 (10.4)0.014Dopamine, g/kg/min0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.020Dobutamine, %128 (4.1)45 (5.7)25 (3.2)12 (1.5)46 (5.8) < 0.001Dobutamine, g/kg/min0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00] < 0.001Epinephrine, %647 (20.6)177 (22.5)211 (26.8)122 (15.5)137 (17.4) < 0.001Epinephrine, g/kg/min0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.02]0.00 [0.00, 0.00]0.00 [0.00, 0.00] < 0.001Norepinephrine, %1573 (50.0)631 (80.2)401 (51.0)349 (44.4)192 (24.4) < 0.001Norepinephrine, g/kg/min0.00 [0.00, 0.15]0.26 [0.08, 0.42]0.04 [0.00, 0.15]0.00 [0.00, 0.09]0.00 [0.00, 0.00] < 0.001Vasopressin, %316 (10.0)214 (27.2)75 (9.5)20 (2.5)7 (0.9) < 0.001Vasopressin, units/kg/min0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00] < 0.001Milrinone, %244 (7.8)96 (12.2)86 (10.9)34 (4.3)28 (3.6) < 0.001Milrinone, g/kg/min0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00] < 0.001Phenylephrine, %1419 (45.1)305 (38.8)377 (47.9)378 (48.1)359 (45.6) < 0.001Phenylephrine, g/kg/min0.00 [0.00, 1.00]0.00 [0.00, 2.00]0.00 [0.00, 1.50]0.00 [0.00, 1.00]0.00 [0.00, 0.50] < 0.001Maximun VIS13.01 [7.00, 25.01]41.74 [30.08, 60.32]18.02 [15.01, 20.88]10.00 [8.01, 11.00]5.00 [3.00, 5.03] < 0.001Count1.00 [1.00, 2.00]2.00 [1.00, 3.00]1.00 [1.00, 2.00]1.00 [1.00, 1.00]1.00 [1.00, 1.00] < 0.001Vital signsHeart rate, bpm82.15 [74.78, 92.15]86.05 [76.82, 98.30]83.21 [76.52, 92.76]80.52 [74.48, 90.21]79.88 [72.94, 87.62] < 0.001SBP, mmHg109.20 [102.85, 115.91]105.45 [99.61, 111.29]108.22 [103.21, 113.96]110.03 [104.12, 116.14]113.50 [106.15, 119.77] < 0.001DBP, mmHg57.00 [51.78, 62.66]56.34 [51.18, 62.69]56.09 [50.87, 61.36]56.93 [51.87, 62.18]58.55 [53.13, 64.01] < 0.001MBP, mmHg72.94 [68.55, 77.54]71.64 [66.90, 76.52]72.18 [68.27, 76.37]72.96 [68.60, 77.28]75.13 [70.47, 79.61] < 0.001Shock index0.59 [0.51, 0.69]0.63 [0.54, 0.74]0.60 [0.52, 0.70]0.59 [0.51, 0.66]0.56 [0.50, 0.64] < 0.001Respiratory rate, br/min18.71 [16.74, 21.22]19.61 [17.32, 22.57]18.64 [16.79, 21.05]18.38 [16.57, 20.66]18.36 [16.45, 20.52] < 0.001Temperature, °C37.22 [36.94, 37.72]37.33 [37.00, 38.00]37.28 [37.00, 37.70]37.20 [36.94, 37.67]37.17 [36.89, 37.60] < 0.001Urine output, ml/24 h1500.00 [975.00, 2295.00]1270.00 [760.50, 2162.50]1498.00 [994.00, 2287.50]1513.00 [1027.00, 2273.75]1675.00 [1155.00, 2410.00] < 0.001Intake, ml/24 h3477.08 [2067.02, 5160.17]4329.88 [2583.15, 6645.09]3798.37 [2299.73, 5361.82]3318.99 [2057.79, 4733.66]2840.65 [1608.77, 4144.77] < 0.001Fluid balance, ml/24 h1172.16 [−206.45, 2778.85]2338.30 [417.62, 4303.95]1441.80 [57.23, 2878.73]950.84 [−210.95, 2321.45]501.31 [−901.83, 1688.63] < 0.001Laboratory test at baselineHemoglobin, g/dL11.50 [10.20, 13.00]11.60 [10.20, 13.10]11.50 [10.20, 13.00]11.30 [10.20, 12.67]11.50 [10.20, 13.00]0.123Write blood cell, 109/L15.80 [11.50, 20.90]17.80 [13.00, 24.45]16.20 [12.25, 21.45]15.20 [10.90, 19.80]14.30 [10.35, 18.60] < 0.001Platelets, 109/L204.00 [157.00, 267.00]210.00 [159.00, 286.50]204.00 [157.00, 259.50]203.00 [155.00, 266.00]203.00 [158.00, 258.00]0.144Albumin, g/L3.60 [3.10, 4.00]3.35 [2.80, 3.80]3.53 [3.20, 3.94]3.60 [3.20, 4.00]3.70 [3.30, 4.10] < 0.001BUN, mg/dL26.00 [18.00, 40.00]30.00 [20.00, 47.00]26.00 [19.00, 38.00]25.00 [18.00, 38.75]24.00 [18.00, 36.00] < 0.001Creatinine, umol/L1.30 [1.00, 1.80]1.40 [1.10, 2.10]1.20 [1.00, 1.70]1.20 [0.90, 1.70]1.20 [0.90, 1.60] < 0.001Glucose, mg/dL147.00 [119.00, 197.00]175.00 [135.00, 240.50]144.00 [120.00, 189.00]139.00 [117.00, 180.75]138.00 [115.00, 174.50] < 0.001Calcium, mmol/L8.60 [8.20, 9.10]8.50 [8.10, 9.10]8.60 [8.20, 9.10]8.60 [8.20, 9.10]8.70 [8.20, 9.10]0.003Chloride, mmol/L107.00 [104.00, 110.00]107.00 [103.00, 110.00]108.00 [104.00, 111.00]107.00 [103.00, 110.00]107.00 [103.00, 110.00]0.019Sodium, mmol/L140.00 [137.00, 142.00]140.00 [137.00, 143.00]140.00 [138.00, 142.00]140.00 [137.00, 142.00]140.00 [138.00, 142.00]0.081Potassium, mmol/L4.70 [4.30, 5.10]4.70 [4.40, 5.30]4.70 [4.40, 5.10]4.60 [4.30, 5.00]4.60 [4.20, 5.00] < 0.001PT, s15.90 [14.00, 18.70]16.70 [14.10, 20.50]16.20 [14.20, 18.55]15.60 [13.90, 18.20]15.60 [13.85, 17.65] < 0.001APTT, s39.00 [31.60, 65.60]41.30 [32.50, 72.10]40.00 [32.15, 66.35]37.30 [31.13, 60.27]38.20 [31.05, 62.10] < 0.001ALT, U/L, % < 0.001Missing1255 (39.9)203 (25.8)341 (43.3)355 (45.2)356 (45.2) < 401194 (37.9)315 (40.0)282 (35.8)298 (37.9)299 (38.0)40–79277 (8.8)90 (11.4)65 (8.3)62 (7.9)60 (7.6)80–200203 (6.5)81 (10.3)50 (6.4)33 (4.2)39 (5.0)≥200218 (6.9)98 (12.5)49 (6.2)38 (4.8)33 (4.2)AST, U/L, % < 0.001Missing1247 (39.6)204 (25.9)337 (42.8)352 (44.8)354 (45.0) < 40882 (28.0)200 (25.4)216 (27.4)231 (29.4)235 (29.9)40–79418 (13.3)129 (16.4)96 (12.2)100 (12.7)93 (11.8)80–200280 (8.9)105 (13.3)68 (8.6)50 (6.4)57 (7.2)≥200320 (10.2)149 (18.9)70 (8.9)53 (6.7)48 (6.1)Total bilirubin, mg/dL, % < 0.001Missing1258 (40.0)209 (26.6)339 (43.1)355 (45.2)355 (45.1) < 11195 (38.0)306 (38.9)291 (37.0)308 (39.2)290 (36.8)1–1.9445 (14.1)160 (20.3)103 (13.1)81 (10.3)101 (12.8)≥2249 (7.9)112 (14.2)54 (6.9)42 (5.3)41 (5.2)Lactate, mmol/L2.60 [1.90, 3.80]3.20 [2.30, 5.35]2.90 [2.00, 4.10]2.40 [1.70, 3.30]2.30 [1.70, 3.15] < 0.001PH7.31 [7.25, 7.35]7.26 [7.19, 7.33]7.30 [7.25, 7.34]7.32 [7.28, 7.36]7.32 [7.28, 7.37] < 0.001Po2, mmHg76.00 [43.00, 104.00]64.00 [39.00, 90.00]77.00 [42.00, 105.00]79.50 [44.00, 108.75]84.00 [58.00, 110.00] < 0.001Pco2, mmHg48.00 [43.00, 54.00]49.00 [43.00, 57.00]48.00 [44.00, 55.00]48.00 [43.00, 54.00]48.00 [43.00, 53.00]0.020Oxygenation Index146.00 [87.50, 231.43]121.67 [72.00, 202.00]146.00 [88.00, 230.00]151.00 [91.25, 238.00]163.00 [100.83, 250.50] < 0.001NT-proBNP, pg/mL, %0.429Missing2294 (72.9)559 (71.0)572 (72.7)579 (73.7)584 (74.2)≤1800215 (6.8)50 (6.4)51 (6.5)57 (7.3)57 (7.2)1801–5000235 (7.5)71 (9.0)56 (7.1)52 (6.6)56 (7.1)5001– 10,000170 (5.4)37 (4.7)52 (6.6)45 (5.7)36 (4.6)≥10001233 (7.4)70 (8.9)56 (7.1)53 (6.7)54 (6.9)TNT, μg/L, % < 0.001Missing1883 (59.8)367 (46.6)483 (61.4)499 (63.5)534 (67.9) < 0.20648 (20.6)211 (26.8)151 (19.2)160 (20.4)126 (16.0)0.20–0.49196 (6.2)50 (6.4)49 (6.2)51 (6.5)46 (5.8)≥0.50420 (13.3)159 (20.2)104 (13.2)76 (9.7)81 (10.3)CKMB, IU/L, % < 0.001Missing1927 (61.2)380 (48.3)503 (63.9)510 (64.9)534 (67.9) < 10712 (22.6)210 (26.7)162 (20.6)176 (22.4)164 (20.8)≥10508 (16.1)197 (25.0)122 (15.5)100 (12.7)89 (11.3)Triglycerides, mg/dL, %0.068Missing2599 (82.6)627 (79.7)655 (83.2)656 (83.5)661 (84.0) < 200472 (15.0)133 (16.9)119 (15.1)116 (14.8)104 (13.2)≥20076 (2.4)27 (3.4)13 (1.7)14 (1.8)22 (2.8)Cholesterol, mg/dL, %0.491Missing2657 (84.4)662 (84.1)667 (84.8)664 (84.5)664 (84.4) < 200412 (13.1)109 (13.9)107 (13.6)100 (12.7)96 (12.2)200–23957 (1.8)10 (1.3)11 (1.4)16 (2.0)20 (2.5)≥24021 (0.7)6 (0.8)2 (0.3)6 (0.8)7 (0.9)HDL-c, mg/dL, %0.743Missing2682 (85.2)666 (84.6)671 (85.3)670 (85.2)675 (85.8) < 40193 (6.1)51 (6.5)56 (7.1)41 (5.2)45 (5.7)41–60186 (5.9)47 (6.0)45 (5.7)50 (6.4)44 (5.6)≥6086 (2.7)23 (2.9)15 (1.9)25 (3.2)23 (2.9)LDL-c, mg/dL, %0.534Missing2686 (85.4)670 (85.1)671 (85.3)672 (85.5)673 (85.5) < 70183 (5.8)42 (5.3)48 (6.1)50 (6.4)43 (5.5)70–100142 (4.5)45 (5.7)37 (4.7)31 (3.9)29 (3.7)≥100136 (4.3)30 (3.8)31 (3.9)33 (4.2)42 (5.3)Hba1c, %, % < 0.001Missing1563 (49.7)480 (61.0)372 (47.3)369 (46.9)342 (43.5) < 5.7423 (13.4)74 (9.4)120 (15.2)119 (15.1)110 (14.0)5.7–6.4628 (20.0)138 (17.5)176 (22.4)144 (18.3)170 (21.6)6.5–6.9168 (5.3)28 (3.6)37 (4.7)56 (7.1)47 (6.0)7–7.9171 (5.4)25 (3.2)44 (5.6)41 (5.2)61 (7.8)≥8194 (6.2)42 (5.3)38 (4.8)57 (7.3)57 (7.2)CRP, mg/L, %0.465Missing3051 (96.9)757 (96.2)770 (97.8)761 (96.8)763 (97.0) < 1012 (0.4)3 (0.4)4 (0.5)3 (0.4)2 (0.3)≥1084 (2.7)27 (3.4)13 (1.7)22 (2.8)22 (2.8)ACR, mg/g, %0.520Missing3092 (98.3)777 (98.7)770 (97.8)771 (98.1)774 (98.3) < 30041 (1.3)7 (0.9)11 (1.4)11 (1.4)12 (1.5)≥30014 (0.4)3 (0.4)6 (0.8)4 (0.5)1 (0.1)ComorbiditiesHypertension, %1009 (32.1)236 (30.0)241 (30.6)277 (35.2)255 (32.4)0.112Acute myocardial infarction, %739 (23.5)204 (25.9)188 (23.9)183 (23.3)164 (20.8)0.124Valve disorder, %1462 (46.5)302 (38.4)386 (49.0)390 (49.6)384 (48.8) < 0.001Atrial fibrillation, %1743 (55.4)428 (54.4)450 (57.2)434 (55.2)431 (54.8)0.688Cardiomyopathy, %436 (13.9)116 (14.7)110 (14.0)98 (12.5)112 (14.2)0.596Peripheral vascular disease, %524 (16.7)160 (20.3)116 (14.7)126 (16.0)122 (15.5)0.013Cerebrovascular disease, %327 (10.4)102 (13.0)75 (9.5)73 (9.3)77 (9.8)0.056Chronic kidney disease, %925 (29.4)237 (30.1)234 (29.7)219 (27.9)235 (29.9)0.750Chronic pulmonary disease, %1107 (35.2)282 (35.8)283 (36.0)282 (35.9)260 (33.0)0.550Pneumonia, %541 (17.2)209 (26.6)107 (13.6)117 (14.9)108 (13.7) < 0.001Liver disease, %273 (8.7)105 (13.3)63 (8.0)56 (7.1)49 (6.2) < 0.001Cancer, %281 (8.9)97 (12.3)73 (9.3)54 (6.9)57 (7.2) < 0.001Diabetes, %1178 (37.4)257 (32.7)290 (36.8)314 (39.9)317 (40.3)0.006Lipoprotein metabolism disorders, %1779 (56.5)402 (51.1)417 (53.0)474 (60.3)486 (61.8) < 0.001Gastrointestinal bleeding, %87 (2.8)34 (4.3)17 (2.2)16 (2.0)20 (2.5)0.020Acute pancreatitis, %33 (1.0)11 (1.4)10 (1.3)5 (0.6)7 (0.9)0.427Sepsis, %1455 (46.2)464 (59.0)360 (45.7)340 (43.3)291 (37.0) < 0.001Shock, %1101 (35.0)471 (59.8)253 (32.1)213 (27.1)164 (20.8) < 0.001Cardiogenic shock, %459 (14.6)209 (26.6)102 (13.0)75 (9.5)73 (9.3) < 0.001Sepsis shock, %558 (17.7)243 (30.9)122 (15.5)119 (15.1)74 (9.4) < 0.001Treatment within 24 hAssist ventilation, %2184 (69.4)624 (79.3)569 (72.3)513 (65.3)478 (60.7) < 0.001IABP, %132 (4.2)54 (6.9)38 (4.8)17 (2.2)23 (2.9) < 0.001Advanced MCS, %98 (3.1)52 (6.6)20 (2.5)9 (1.1)17 (2.2) < 0.001ECMO, %12 (0.4)8 (1.0)4 (0.5)0 (0.0)0 (0.0)0.002Impella, %20 (0.6)13 (1.7)4 (0.5)0 (0.0)3 (0.4) < 0.001Tandem heart, %4 (0.1)3 (0.4)0 (0.0)0 (0.0)1 (0.1)0.111Heart assist system %13 (0.4)8 (1.0)3 (0.4)0 (0.0)2 (0.3)0.013Blood transfusion, % < 0.001No2332 (74.1)509 (64.7)551 (70.0)610 (77.6)662 (84.1)Red blood cell604 (19.2)199 (25.3)165 (21.0)145 (18.4)95 (12.1)Others211 (6.7)79 (10.0)71 (9.0)31 (3.9)30 (3.8)Medication at baselineACEI/ARB, %681 (21.6)134 (17.0)182 (23.1)191 (24.3)174 (22.1)0.003Amiodarone, %503 (16.0)162 (20.6)128 (16.3)113 (14.4)100 (12.7) < 0.001Anticoagulants, %416 (13.2)91 (11.6)105 (13.3)107 (13.6)113 (14.4)0.409Vitamin k antagonists, %304 (9.7)60 (7.6)77 (9.8)80 (10.2)87 (11.1)0.125NOACS, %117 (3.7)32 (4.1)30 (3.8)28 (3.6)27 (3.4)0.914CCB, %516 (16.4)92 (11.7)115 (14.6)141 (17.9)168 (21.3) < 0.001Digoxin, %194 (6.2)47 (6.0)50 (6.4)49 (6.2)48 (6.1)0.990Loop diuretic, %2039 (64.8)465 (59.1)503 (63.9)515 (65.5)556 (70.6) < 0.001Sparing diuretics, %128 (4.1)36 (4.6)26 (3.3)35 (4.5)31 (3.9)0.567NSAID, %2261 (71.8)487 (61.9)593 (75.3)570 (72.5)611 (77.6) < 0.001Beta blocker, %1714 (54.5)344 (43.7)430 (54.6)456 (58.0)484 (61.5) < 0.001Hypolipidemic drug, %1813 (57.6)397 (50.4)440 (55.9)473 (60.2)503 (63.9) < 0.001Antibiotics, %2759 (87.7)700 (88.9)703 (89.3)697 (88.7)659 (83.7)0.002BPRI quartile: Q1: 0.01–2.37; Q2: 2.37–4.77; Q3: 4.77–9.37; Q4: 9.37–91.97. BPRI, Blood Pressure Response Index; MAP, Mean Arterial Pressure; VIS, Vasoactive–Inotropic Score; AKI, Acute Kidney Injury; BMI: Body Mass Index; HF: Heart Failure; AHF: Acute Heart Failure; CHF: Chronic Heart Failure; AECHF: Acute Exacerbation of Chronic Heart Failure; APS: Acute physiology score; SOFA score: Sequential Organ Failure Assessment score; SIRS: Systemic Inflammatory Response Syndrome; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; MBP: Mean Blood Pressure; BUN: Blood Urea Nitrogen; PT: Prothrombin Time; APTT: Activated Partial Thromboplastin Time; ALT: Alanine Aminotransferase; AST: Aspartate Aminotransferase; pH: Potential of Hydrogen; PaO₂: Partial Pressure of Oxygen; PaCO₂: Partial Pressure of Carbon Dioxide; HDL-C: High-Density Lipoprotein Cholesterol; LDL-C: Low-Density Lipoprotein Cholesterol; HbA1c: Glycated Hemoglobin; CRP: C-Reactive Protein; ACR: Albumin-to-Creatinine Ratio; MCS: Mechanical Circulatory Support; ECMO: Extracorporeal Membrane Oxygenation; ACEI/ARB: Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker; NOACs: Non-Vitamin K Antagonist Oral Anticoagulants; CCB: Calcium Channel Blocker; NSAID: Nonsteroidal Anti-Inflammatory Drug Table 1Baseline characteristics according to BPRI index quartilesVariablesOverallGroup divided by BPRIP valueQ1Q2Q3Q4General characteristicsMale, %1883 (59.8)465 (59.1)482 (61.2)462 (58.8)474 (60.2)0.741Age, years73.80 [64.50, 82.33]74.60 [64.89, 82.89]75.08 [66.23, 82.70]74.07 [64.80, 82.80]71.74 [62.63, 80.50] < 0.001Race, %0.196 White2239 (71.1)532 (67.6)562 (71.4)586 (74.6)559 (71.0) Black188 (6.0)51 (6.5)46 (5.8)36 (4.6)55 (7.0) Asian77 (2.4)24 (3.0)18 (2.3)16 (2.0)19 (2.4) Others643 (20.4)180 (22.9)161 (20.5)148 (18.8)154 (19.6)BMI, kg/m228.34 [24.42, 33.08]27.81 [24.03, 32.41]28.30 [24.35, 32.66]28.35 [24.69, 33.11]28.89 [24.84, 34.12]0.007Surgery, %886 (28.2)136 (17.3)236 (30.0)235 (29.9)279 (35.5) < 0.001Classification of HF, % < 0.001 AHF517 (16.4)172 (21.9)130 (16.5)109 (13.9)106 (13.5) CHF977 (31.0)188 (23.9)249 (31.6)264 (33.6)276 (35.1) AECHF1076 (34.2)304 (38.6)267 (33.9)271 (34.5)234 (29.7)Not described577 (18.3)123 (15.6)141 (17.9)142 (18.1)171 (21.7)Right heart failure, %25 (0.8)7 (0.9)6 (0.8)5 (0.6)7 (0.9)0.932BPRI (minimum of 24 h)4.77 [2.37, 9.37]1.32 [0.79, 1.80]3.48 [2.90, 4.08]6.50 [5.63, 7.62]13.80 [11.40, 20.66] < 0.001VIS (at the time of the minimum BPRI)12.01 [7.00, 23.01]40.05 [30.01, 56.40]17.97 [15.00, 20.03]10.00 [8.00, 10.02]5.00 [3.00, 5.00] < 0.001MBP (at the time of the minimum BPRI)61.00 [54.00, 69.00]56.00 [46.00, 64.00]60.00 [53.00, 67.00]63.00 [57.00, 69.00]66.00 [59.00, 74.00] < 0.001Charlson comorbidity index6.00 [5.00, 8.00]7.00 [5.00, 8.00]6.00 [5.00, 8.00]6.00 [5.00, 8.00]6.00 [5.00, 8.00] < 0.001APS 45.00 [34.00, 59.00]55.00 [43.50, 72.00]44.00 [35.00, 58.00]42.00 [32.00, 55.00]40.00 [31.00, 51.00] < 0.001SOFA score7.00 [5.00, 9.00]7.00 [5.00, 9.00]7.00 [5.00, 9.00]7.00 [5.00, 9.00]7.00 [5.00, 9.00]0.236SIRS3.00 [2.00, 3.00]3.00 [3.00, 4.00]3.00 [2.00, 3.00]3.00 [2.00, 3.00]3.00 [2.00, 3.00] < 0.001Situation of AKI within 24 h < 0.001No AKI1106 (35.1)219 (27.8)289 (36.7)297 (37.8)301 (38.2)Stage 1732 (23.3)176 (22.4)190 (24.1)165 (21.0)201 (25.5)Stage 21309 (41.6)392 (49.8)308 (39.1)324 (41.2)285 (36.2)Vasoactive drug and maximum dosage used within 24 hDopamine, %273 (8.7)80 (10.2)58 (7.4)53 (6.7)82 (10.4)0.014Dopamine, g/kg/min0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.020Dobutamine, %128 (4.1)45 (5.7)25 (3.2)12 (1.5)46 (5.8) < 0.001Dobutamine, g/kg/min0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00] < 0.001Epinephrine, %647 (20.6)177 (22.5)211 (26.8)122 (15.5)137 (17.4) < 0.001Epinephrine, g/kg/min0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.02]0.00 [0.00, 0.00]0.00 [0.00, 0.00] < 0.001Norepinephrine, %1573 (50.0)631 (80.2)401 (51.0)349 (44.4)192 (24.4) < 0.001Norepinephrine, g/kg/min0.00 [0.00, 0.15]0.26 [0.08, 0.42]0.04 [0.00, 0.15]0.00 [0.00, 0.09]0.00 [0.00, 0.00] < 0.001Vasopressin, %316 (10.0)214 (27.2)75 (9.5)20 (2.5)7 (0.9) < 0.001Vasopressin, units/kg/min0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00] < 0.001Milrinone, %244 (7.8)96 (12.2)86 (10.9)34 (4.3)28 (3.6) < 0.001Milrinone, g/kg/min0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00]0.00 [0.00, 0.00] < 0.001Phenylephrine, %1419 (45.1)305 (38.8)377 (47.9)378 (48.1)359 (45.6) < 0.001Phenylephrine, g/kg/min0.00 [0.00, 1.00]0.00 [0.00, 2.00]0.00 [0.00, 1.50]0.00 [0.00, 1.00]0.00 [0.00, 0.50] < 0.001Maximun VIS13.01 [7.00, 25.01]41.74 [30.08, 60.32]18.02 [15.01, 20.88]10.00 [8.01, 11.00]5.00 [3.00, 5.03] < 0.001Count1.00 [1.00, 2.00]2.00 [1.00, 3.00]1.00 [1.00, 2.00]1.00 [1.00, 1.00]1.00 [1.00, 1.00] < 0.001Vital signsHeart rate, bpm82.15 [74.78, 92.15]86.05 [76.82, 98.30]83.21 [76.52, 92.76]80.52 [74.48, 90.21]79.88 [72.94, 87.62] < 0.001SBP, mmHg109.20 [102.85, 115.91]105.45 [99.61, 111.29]108.22 [103.21, 113.96]110.03 [104.12, 116.14]113.50 [106.15, 119.77] < 0.001DBP, mmHg57.00 [51.78, 62.66]56.34 [51.18, 62.69]56.09 [50.87, 61.36]56.93 [51.87, 62.18]58.55 [53.13, 64.01] < 0.001MBP, mmHg72.94 [68.55, 77.54]71.64 [66.90, 76.52]72.18 [68.27, 76.37]72.96 [68.60, 77.28]75.13 [70.47, 79.61] < 0.001Shock index0.59 [0.51, 0.69]0.63 [0.54, 0.74]0.60 [0.52, 0.70]0.59 [0.51, 0.66]0.56 [0.50, 0.64] < 0.001Respiratory rate, br/min18.71 [16.74, 21.22]19.61 [17.32, 22.57]18.64 [16.79, 21.05]18.38 [16.57, 20.66]18.36 [16.45, 20.52] < 0.001Temperature, °C37.22 [36.94, 37.72]37.33 [37.00, 38.00]37.28 [37.00, 37.70]37.20 [36.94, 37.67]37.17 [36.89, 37.60] < 0.001Urine output, ml/24 h1500.00 [975.00, 2295.00]1270.00 [760.50, 2162.50]1498.00 [994.00, 2287.50]1513.00 [1027.00, 2273.75]1675.00 [1155.00, 2410.00] < 0.001Intake, ml/24 h3477.08 [2067.02, 5160.17]4329.88 [2583.15, 6645.09]3798.37 [2299.73, 5361.82]3318.99 [2057.79, 4733.66]2840.65 [1608.77, 4144.77] < 0.001Fluid balance, ml/24 h1172.16 [−206.45, 2778.85]2338.30 [417.62, 4303.95]1441.80 [57.23, 2878.73]950.84 [−210.95, 2321.45]501.31 [−901.83, 1688.63] < 0.001Laboratory test at baselineHemoglobin, g/dL11.50 [10.20, 13.00]11.60 [10.20, 13.10]11.50 [10.20, 13.00]11.30 [10.20, 12.67]11.50 [10.20, 13.00]0.123Write blood cell, 109/L15.80 [11.50, 20.90]17.80 [13.00, 24.45]16.20 [12.25, 21.45]15.20 [10.90, 19.80]14.30 [10.35, 18.60] < 0.001Platelets, 109/L204.00 [157.00, 267.00]210.00 [159.00, 286.50]204.00 [157.00, 259.50]203.00 [155.00, 266.00]203.00 [158.00, 258.00]0.144Albumin, g/L3.60 [3.10, 4.00]3.35 [2.80, 3.80]3.53 [3.20, 3.94]3.60 [3.20, 4.00]3.70 [3.30, 4.10] < 0.001BUN, mg/dL26.00 [18.00, 40.00]30.00 [20.00, 47.00]26.00 [19.00, 38.00]25.00 [18.00, 38.75]24.00 [18.00, 36.00] < 0.001Creatinine, umol/L1.30 [1.00, 1.80]1.40 [1.10, 2.10]1.20 [1.00, 1.70]1.20 [0.90, 1.70]1.20 [0.90, 1.60] < 0.001Glucose, mg/dL147.00 [119.00, 197.00]175.00 [135.00, 240.50]144.00 [120.00, 189.00]139.00 [117.00, 180.75]138.00 [115.00, 174.50] < 0.001Calcium, mmol/L8.60 [8.20, 9.10]8.50 [8.10, 9.10]8.60 [8.20, 9.10]8.60 [8.20, 9.10]8.70 [8.20, 9.10]0.003Chloride, mmol/L107.00 [104.00, 110.00]107.00 [103.00, 110.00]108.00 [104.00, 111.00]107.00 [103.00, 110.00]107.00 [103.00, 110.00]0.019Sodium, mmol/L140.00 [137.00, 142.00]140.00 [137.00, 143.00]140.00 [138.00, 142.00]140.00 [137.00, 142.00]140.00 [138.00, 142.00]0.081Potassium, mmol/L4.70 [4.30, 5.10]4.70 [4.40, 5.30]4.70 [4.40, 5.10]4.60 [4.30, 5.00]4.60 [4.20, 5.00] < 0.001PT, s15.90 [14.00, 18.70]16.70 [14.10, 20.50]16.20 [14.20, 18.55]15.60 [13.90, 18.20]15.60 [13.85, 17.65] < 0.001APTT, s39.00 [31.60, 65.60]41.30 [32.50, 72.10]40.00 [32.15, 66.35]37.30 [31.13, 60.27]38.20 [31.05, 62.10] < 0.001ALT, U/L, % < 0.001Missing1255 (39.9)203 (25.8)341 (43.3)355 (45.2)356 (45.2) < 401194 (37.9)315 (40.0)282 (35.8)298 (37.9)299 (38.0)40–79277 (8.8)90 (11.4)65 (8.3)62 (7.9)60 (7.6)80–200203 (6.5)81 (10.3)50 (6.4)33 (4.2)39 (5.0)≥200218 (6.9)98 (12.5)49 (6.2)38 (4.8)33 (4.2)AST, U/L, % < 0.001Missing1247 (39.6)204 (25.9)337 (42.8)352 (44.8)354 (45.0) < 40882 (28.0)200 (25.4)216 (27.4)231 (29.4)235 (29.9)40–79418 (13.3)129 (16.4)96 (12.2)100 (12.7)93 (11.8)80–200280 (8.9)105 (13.3)68 (8.6)50 (6.4)57 (7.2)≥200320 (10.2)149 (18.9)70 (8.9)53 (6.7)48 (6.1)Total bilirubin, mg/dL, % < 0.001Missing1258 (40.0)209 (26.6)339 (43.1)355 (45.2)355 (45.1) < 11195 (38.0)306 (38.9)291 (37.0)308 (39.2)290 (36.8)1–1.9445 (14.1)160 (20.3)103 (13.1)81 (10.3)101 (12.8)≥2249 (7.9)112 (14.2)54 (6.9)42 (5.3)41 (5.2)Lactate, mmol/L2.60 [1.90, 3.80]3.20 [2.30, 5.35]2.90 [2.00, 4.10]2.40 [1.70, 3.30]2.30 [1.70, 3.15] < 0.001PH7.31 [7.25, 7.35]7.26 [7.19, 7.33]7.30 [7.25, 7.34]7.32 [7.28, 7.36]7.32 [7.28, 7.37] < 0.001Po2, mmHg76.00 [43.00, 104.00]64.00 [39.00, 90.00]77.00 [42.00, 105.00]79.50 [44.00, 108.75]84.00 [58.00, 110.00] < 0.001Pco2, mmHg48.00 [43.00, 54.00]49.00 [43.00, 57.00]48.00 [44.00, 55.00]48.00 [43.00, 54.00]48.00 [43.00, 53.00]0.020Oxygenation Index146.00 [87.50, 231.43]121.67 [72.00, 202.00]146.00 [88.00, 230.00]151.00 [91.25, 238.00]163.00 [100.83, 250.50] < 0.001NT-proBNP, pg/mL, %0.429Missing2294 (72.9)559 (71.0)572 (72.7)579 (73.7)584 (74.2)≤1800215 (6.8)50 (6.4)51 (6.5)57 (7.3)57 (7.2)1801–5000235 (7.5)71 (9.0)56 (7.1)52 (6.6)56 (7.1)5001– 10,000170 (5.4)37 (4.7)52 (6.6)45 (5.7)36 (4.6)≥10001233 (7.4)70 (8.9)56 (7.1)53 (6.7)54 (6.9)TNT, μg/L, % < 0.001Missing1883 (59.8)367 (46.6)483 (61.4)499 (63.5)534 (67.9) < 0.20648 (20.6)211 (26.8)151 (19.2)160 (20.4)126 (16.0)0.20–0.49196 (6.2)50 (6.4)49 (6.2)51 (6.5)46 (5.8)≥0.50420 (13.3)159 (20.2)104 (13.2)76 (9.7)81 (10.3)CKMB, IU/L, % < 0.001Missing1927 (61.2)380 (48.3)503 (63.9)510 (64.9)534 (67.9) < 10712 (22.6)210 (26.7)162 (20.6)176 (22.4)164 (20.8)≥10508 (16.1)197 (25.0)122 (15.5)100 (12.7)89 (11.3)Triglycerides, mg/dL, %0.068Missing2599 (82.6)627 (79.7)655 (83.2)656 (83.5)661 (84.0) < 200472 (15.0)133 (16.9)119 (15.1)116 (14.8)104 (13.2)≥20076 (2.4)27 (3.4)13 (1.7)14 (1.8)22 (2.8)Cholesterol, mg/dL, %0.491Missing2657 (84.4)662 (84.1)667 (84.8)664 (84.5)664 (84.4) < 200412 (13.1)109 (13.9)107 (13.6)100 (12.7)96 (12.2)200–23957 (1.8)10 (1.3)11 (1.4)16 (2.0)20 (2.5)≥24021 (0.7)6 (0.8)2 (0.3)6 (0.8)7 (0.9)HDL-c, mg/dL, %0.743Missing2682 (85.2)666 (84.6)671 (85.3)670 (85.2)675 (85.8) < 40193 (6.1)51 (6.5)56 (7.1)41 (5.2)45 (5.7)41–60186 (5.9)47 (6.0)45 (5.7)50 (6.4)44 (5.6)≥6086 (2.7)23 (2.9)15 (1.9)25 (3.2)23 (2.9)LDL-c, mg/dL, %0.534Missing2686 (85.4)670 (85.1)671 (85.3)672 (85.5)673 (85.5) < 70183 (5.8)42 (5.3)48 (6.1)50 (6.4)43 (5.5)70–100142 (4.5)45 (5.7)37 (4.7)31 (3.9)29 (3.7)≥100136 (4.3)30 (3.8)31 (3.9)33 (4.2)42 (5.3)Hba1c, %, % < 0.001Missing1563 (49.7)480 (61.0)372 (47.3)369 (46.9)342 (43.5) < 5.7423 (13.4)74 (9.4)120 (15.2)119 (15.1)110 (14.0)5.7–6.4628 (20.0)138 (17.5)176 (22.4)144 (18.3)170 (21.6)6.5–6.9168 (5.3)28 (3.6)37 (4.7)56 (7.1)47 (6.0)7–7.9171 (5.4)25 (3.2)44 (5.6)41 (5.2)61 (7.8)≥8194 (6.2)42 (5.3)38 (4.8)57 (7.3)57 (7.2)CRP, mg/L, %0.465Missing3051 (96.9)757 (96.2)770 (97.8)761 (96.8)763 (97.0) < 1012 (0.4)3 (0.4)4 (0.5)3 (0.4)2 (0.3)≥1084 (2.7)27 (3.4)13 (1.7)22 (2.8)22 (2.8)ACR, mg/g, %0.520Missing3092 (98.3)777 (98.7)770 (97.8)771 (98.1)774 (98.3) < 30041 (1.3)7 (0.9)11 (1.4)11 (1.4)12 (1.5)≥30014 (0.4)3 (0.4)6 (0.8)4 (0.5)1 (0.1)ComorbiditiesHypertension, %1009 (32.1)236 (30.0)241 (30.6)277 (35.2)255 (32.4)0.112Acute myocardial infarction, %739 (23.5)204 (25.9)188 (23.9)183 (23.3)164 (20.8)0.124Valve disorder, %1462 (46.5)302 (38.4)386 (49.0)390 (49.6)384 (48.8) < 0.001Atrial fibrillation, %1743 (55.4)428 (54.4)450 (57.2)434 (55.2)431 (54.8)0.688Cardiomyopathy, %436 (13.9)116 (14.7)110 (14.0)98 (12.5)112 (14.2)0.596Peripheral vascular disease, %524 (16.7)160 (20.3)116 (14.7)126 (16.0)122 (15.5)0.013Cerebrovascular disease, %327 (10.4)102 (13.0)75 (9.5)73 (9.3)77 (9.8)0.056Chronic kidney disease, %925 (29.4)237 (30.1)234 (29.7)219 (27.9)235 (29.9)0.750Chronic pulmonary disease, %1107 (35.2)282 (35.8)283 (36.0)282 (35.9)260 (33.0)0.550Pneumonia, %541 (17.2)209 (26.6)107 (13.6)117 (14.9)108 (13.7) < 0.001Liver disease, %273 (8.7)105 (13.3)63 (8.0)56 (7.1)49 (6.2) < 0.001Cancer, %281 (8.9)97 (12.3)73 (9.3)54 (6.9)57 (7.2) < 0.001Diabetes, %1178 (37.4)257 (32.7)290 (36.8)314 (39.9)317 (40.3)0.006Lipoprotein metabolism disorders, %1779 (56.5)402 (51.1)417 (53.0)474 (60.3)486 (61.8) < 0.001Gastrointestinal bleeding, %87 (2.8)34 (4.3)17 (2.2)16 (2.0)20 (2.5)0.020Acute pancreatitis, %33 (1.0)11 (1.4)10 (1.3)5 (0.6)7 (0.9)0.427Sepsis, %1455 (46.2)464 (59.0)360 (45.7)340 (43.3)291 (37.0) < 0.001Shock, %1101 (35.0)471 (59.8)253 (32.1)213 (27.1)164 (20.8) < 0.001Cardiogenic shock, %459 (14.6)209 (26.6)102 (13.0)75 (9.5)73 (9.3) < 0.001Sepsis shock, %558 (17.7)243 (30.9)122 (15.5)119 (15.1)74 (9.4) < 0.001Treatment within 24 hAssist ventilation, %2184 (69.4)624 (79.3)569 (72.3)513 (65.3)478 (60.7) < 0.001IABP, %132 (4.2)54 (6.9)38 (4.8)17 (2.2)23 (2.9) < 0.001Advanced MCS, %98 (3.1)52 (6.6)20 (2.5)9 (1.1)17 (2.2) < 0.001ECMO, %12 (0.4)8 (1.0)4 (0.5)0 (0.0)0 (0.0)0.002Impella, %20 (0.6)13 (1.7)4 (0.5)0 (0.0)3 (0.4) < 0.001Tandem heart, %4 (0.1)3 (0.4)0 (0.0)0 (0.0)1 (0.1)0.111Heart assist system %13 (0.4)8 (1.0)3 (0.4)0 (0.0)2 (0.3)0.013Blood transfusion, % < 0.001No2332 (74.1)509 (64.7)551 (70.0)610 (77.6)662 (84.1)Red blood cell604 (19.2)199 (25.3)165 (21.0)145 (18.4)95 (12.1)Others211 (6.7)79 (10.0)71 (9.0)31 (3.9)30 (3.8)Medication at baselineACEI/ARB, %681 (21.6)134 (17.0)182 (23.1)191 (24.3)174 (22.1)0.003Amiodarone, %503 (16.0)162 (20.6)128 (16.3)113 (14.4)100 (12.7) < 0.001Anticoagulants, %416 (13.2)91 (11.6)105 (13.3)107 (13.6)113 (14.4)0.409Vitamin k antagonists, %304 (9.7)60 (7.6)77 (9.8)80 (10.2)87 (11.1)0.125NOACS, %117 (3.7)32 (4.1)30 (3.8)28 (3.6)27 (3.4)0.914CCB, %516 (16.4)92 (11.7)115 (14.6)141 (17.9)168 (21.3) < 0.001Digoxin, %194 (6.2)47 (6.0)50 (6.4)49 (6.2)48 (6.1)0.990Loop diuretic, %2039 (64.8)465 (59.1)503 (63.9)515 (65.5)556 (70.6) < 0.001Sparing diuretics, %128 (4.1)36 (4.6)26 (3.3)35 (4.5)31 (3.9)0.567NSAID, %2261 (71.8)487 (61.9)593 (75.3)570 (72.5)611 (77.6) < 0.001Beta blocker, %1714 (54.5)344 (43.7)430 (54.6)456 (58.0)484 (61.5) < 0.001Hypolipidemic drug, %1813 (57.6)397 (50.4)440 (55.9)473 (60.2)503 (63.9) < 0.001Antibiotics, %2759 (87.7)700 (88.9)703 (89.3)697 (88.7)659 (83.7)0.002BPRI quartile: Q1: 0.01–2.37; Q2: 2.37–4.77; Q3: 4.77–9.37; Q4: 9.37–91.97. BPRI, Blood Pressure Response Index; MAP, Mean Arterial Pressure; VIS, Vasoactive–Inotropic Score; AKI, Acute Kidney Injury; BMI: Body Mass Index; HF: Heart Failure; AHF: Acute Heart Failure; CHF: Chronic Heart Failure; AECHF: Acute Exacerbation of Chronic Heart Failure; APS: Acute physiology score; SOFA score: Sequential Organ Failure Assessment score; SIRS: Systemic Inflammatory Response Syndrome; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; MBP: Mean Blood Pressure; BUN: Blood Urea Nitrogen; PT: Prothrombin Time; APTT: Activated Partial Thromboplastin Time; ALT: Alanine Aminotransferase; AST: Aspartate Aminotransferase; pH: Potential of Hydrogen; PaO₂: Partial Pressure of Oxygen; PaCO₂: Partial Pressure of Carbon Dioxide; HDL-C: High-Density Lipoprotein Cholesterol; LDL-C: Low-Density Lipoprotein Cholesterol; HbA1c: Glycated Hemoglobin; CRP: C-Reactive Protein; ACR: Albumin-to-Creatinine Ratio; MCS: Mechanical Circulatory Support; ECMO: Extracorporeal Membrane Oxygenation; ACEI/ARB: Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker; NOACs: Non-Vitamin K Antagonist Oral Anticoagulants; CCB: Calcium Channel Blocker; NSAID: Nonsteroidal Anti-Inflammatory Drug Baseline characteristics according to BPRI index quartiles BPRI quartile: Q1: 0.01–2.37; Q2: 2.37–4.77; Q3: 4.77–9.37; Q4: 9.37–91.97. BPRI, Blood Pressure Response Index; MAP, Mean Arterial Pressure; VIS, Vasoactive–Inotropic Score; AKI, Acute Kidney Injury; BMI: Body Mass Index; HF: Heart Failure; AHF: Acute Heart Failure; CHF: Chronic Heart Failure; AECHF: Acute Exacerbation of Chronic Heart Failure; APS: Acute physiology score; SOFA score: Sequential Organ Failure Assessment score; SIRS: Systemic Inflammatory Response Syndrome; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; MBP: Mean Blood Pressure; BUN: Blood Urea Nitrogen; PT: Prothrombin Time; APTT: Activated Partial Thromboplastin Time; ALT: Alanine Aminotransferase; AST: Aspartate Aminotransferase; pH: Potential of Hydrogen; PaO₂: Partial Pressure of Oxygen; PaCO₂: Partial Pressure of Carbon Dioxide; HDL-C: High-Density Lipoprotein Cholesterol; LDL-C: Low-Density Lipoprotein Cholesterol; HbA1c: Glycated Hemoglobin; CRP: C-Reactive Protein; ACR: Albumin-to-Creatinine Ratio; MCS: Mechanical Circulatory Support; ECMO: Extracorporeal Membrane Oxygenation; ACEI/ARB: Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker; NOACs: Non-Vitamin K Antagonist Oral Anticoagulants; CCB: Calcium Channel Blocker; NSAID: Nonsteroidal Anti-Inflammatory Drug Kaplan-meier survival analyses In the Kaplan–Meier analysis based on BPRI quartiles, patients in the Q1 group demonstrated the lowest 90-day survival rate across the entire study population, regardless of whether they experienced AKI progression (log-rank p < 0.001). Only fewer than 50% of the patients in the Q1 group survived, especially those who encountered AKI progression. Additionally, the survival rate decreased rapidly in the first 30-day and remained stable after 30 days. Notably, only 30% of Q1 group patients who progressed to AKI stage 3 survived (Fig. 2, Fig. S1).Fig. 2Kaplan–Meier analysis curve for 90-day mortality based on the BPRI quartile. A: for the whole study population; B: for the patients with AKI progression; C. for the patients without AKI progression Kaplan–Meier analysis curve for 90-day mortality based on the BPRI quartile. A: for the whole study population; B: for the patients with AKI progression; C. for the patients without AKI progression Logistic analyses Table S5 presented the results of univariate logistic regression. When considering BPRI as a continuous variable, BPRI was significantly associated with the risk of AKI progression in unadjusted and adjusted models (all p < 0.05). When categorizing the BPRI quartiles, patients in the higher BPRI quartile were significantly associated with a lower incidence of AKI progression in four models (all OR < 1 and p < 0.05), and Q3 group had the lowest risk in unadjusted model (Model1: OR 0.50, 95% CI 0.41–0.61 and full adjusted models (Model3: OR 0.60, 95% CI 0.48–0.75; Model4: OR 0.64, 95% CI 0.52–0.79 (Table 3). In addition, we observed similar results for the relationship between BPRI and the incidence of AKI stage 3 (Table S6). According to RCS analysis, asymmetric U-shaped association was observed between BPRI and AKI progression in unadjusted and adjusted models, with a cut-off value of 12.0 (all P-overall < 0.05 and all P-non-linear < 0.05). Both elevated and reduced BPRI were related to a higher risk of AKI progression, while the risk of AKI progression changed more rapidly when BPRI below the cut-off value (Fig. 3, Fig. S2). A U-shaped relationship between BPRI and AKI stage 3 was observed, with a cut-off value of 12.3 (Fig. S3).Table 2Clinical outcomes according to BPRI quartilesVariablesOverallGroup divided by BPRIP valueQ1Q2Q3Q4AKI related outcomes 24 to 72 hoursAKI progression, %1571 (49.9)472 (60.0)418 (53.1)336 (42.7)345 (43.8) < 0.001AKI stage 3, %585 (18.6)235 (29.9)146 (18.6)104 (13.2)100 (12.7) < 0.001Need for RRT, %117 (3.7)60 (7.6)23 (2.9)17 (2.2)17 (2.2) < 0.001New arrhythmia within 14 daysNew atrial fibrillation, %516 (16.4)154 (19.6)156 (19.8)105 (13.4)101 (12.8) < 0.001Ventricular tachycardia, %15 (0.5)3 (0.4)7 (0.9)3 (0.4)2 (0.3)0.267Ventricular fibrillation, %51 (1.6)24 (3.0)12 (1.5)9 (1.1)6 (0.8)0.002Asystole, %21 (0.7)12 (1.5)4 (0.5)1 (0.1)4 (0.5)0.005Intensive medication within 14 daysNew use of MCS*, %11 (0.3)6 (0.8)3 (0.4)0 (0.0)2 (0.3)0.077Escalation of vasoactive agents 24 to 48 h, %10 (0.3)6 (0.8)2 (0.3)1 (0.1)1 (0.1)0.078Escalation of vasoactive agents 48 to 72 h, %38 (1.2)31 (3.9)4 (0.5)1 (0.1)2 (0.3) < 0.001MortalityHospital mortality, %287 (9.1)147 (18.7)63 (8.0)41 (5.2)36 (4.6) < 0.001Mortality within 90-day, %1218 (38.7)409 (52.0)293 (37.2)270 (34.4)246 (31.3) < 0.001Survival days within 90-day, days90.00 [12.93, 90.00]39.70 [11.22, 90.00]90.00 [14.37, 90.00]90.00 [13.81, 90.00]90.00 [13.97, 90.00] < 0.001Hospital related outcomesHospital length of stay, days9.19 [6.24, 14.24]11.81 [7.27, 17.86]9.81 [6.82, 14.26]8.44 [6.00, 12.92]7.95 [5.60, 12.52] < 0.001ICU length of stay, days3.04 [1.90, 5.10]4.92 [2.96, 8.08]3.17 [2.11, 5.11]2.41 [1.49, 4.03]2.16 [1.34, 3.33] < 0.001Rehospitalization within 90-day,%286 (9.1)88 (11.2)54 (6.9)76 (9.7)68 (8.6)0.024* Atrial fibrillation did not occur within the first 24 hours of ICU admission but developed within the subsequent 14 days. ** MCS includes Impella, TandemHeart, venoarterial extracorporeal membrane oxygenation, or surgical ventricular assist deviceFig. 3Restricted cubic spline analysis of the relationship between BPRI and AKI progression, adjusted for confounding factors using Model 4. A U-shaped association was observed with a cut-off value of 12.0. Stratified by initial AKI status within the first 24 hours of ICU stay (T0), U-shaped relationships were found in patients without AKI or with AKI stage 2 at T0, while an L-shaped relationship was observed in those with AKI stage 1. A: Whole population; B: The patients without AKI at T0; C. The patients occurred AKI stage 1 at T0; D: The patients occurred AKI stage 2 at T0 Table 2Clinical outcomes according to BPRI quartilesVariablesOverallGroup divided by BPRIP valueQ1Q2Q3Q4AKI related outcomes 24 to 72 hoursAKI progression, %1571 (49.9)472 (60.0)418 (53.1)336 (42.7)345 (43.8) < 0.001AKI stage 3, %585 (18.6)235 (29.9)146 (18.6)104 (13.2)100 (12.7) < 0.001Need for RRT, %117 (3.7)60 (7.6)23 (2.9)17 (2.2)17 (2.2) < 0.001New arrhythmia within 14 daysNew atrial fibrillation, %516 (16.4)154 (19.6)156 (19.8)105 (13.4)101 (12.8) < 0.001Ventricular tachycardia, %15 (0.5)3 (0.4)7 (0.9)3 (0.4)2 (0.3)0.267Ventricular fibrillation, %51 (1.6)24 (3.0)12 (1.5)9 (1.1)6 (0.8)0.002Asystole, %21 (0.7)12 (1.5)4 (0.5)1 (0.1)4 (0.5)0.005Intensive medication within 14 daysNew use of MCS*, %11 (0.3)6 (0.8)3 (0.4)0 (0.0)2 (0.3)0.077Escalation of vasoactive agents 24 to 48 h, %10 (0.3)6 (0.8)2 (0.3)1 (0.1)1 (0.1)0.078Escalation of vasoactive agents 48 to 72 h, %38 (1.2)31 (3.9)4 (0.5)1 (0.1)2 (0.3) < 0.001MortalityHospital mortality, %287 (9.1)147 (18.7)63 (8.0)41 (5.2)36 (4.6) < 0.001Mortality within 90-day, %1218 (38.7)409 (52.0)293 (37.2)270 (34.4)246 (31.3) < 0.001Survival days within 90-day, days90.00 [12.93, 90.00]39.70 [11.22, 90.00]90.00 [14.37, 90.00]90.00 [13.81, 90.00]90.00 [13.97, 90.00] < 0.001Hospital related outcomesHospital length of stay, days9.19 [6.24, 14.24]11.81 [7.27, 17.86]9.81 [6.82, 14.26]8.44 [6.00, 12.92]7.95 [5.60, 12.52] < 0.001ICU length of stay, days3.04 [1.90, 5.10]4.92 [2.96, 8.08]3.17 [2.11, 5.11]2.41 [1.49, 4.03]2.16 [1.34, 3.33] < 0.001Rehospitalization within 90-day,%286 (9.1)88 (11.2)54 (6.9)76 (9.7)68 (8.6)0.024* Atrial fibrillation did not occur within the first 24 hours of ICU admission but developed within the subsequent 14 days. ** MCS includes Impella, TandemHeart, venoarterial extracorporeal membrane oxygenation, or surgical ventricular assist device Clinical outcomes according to BPRI quartiles * Atrial fibrillation did not occur within the first 24 hours of ICU admission but developed within the subsequent 14 days. ** MCS includes Impella, TandemHeart, venoarterial extracorporeal membrane oxygenation, or surgical ventricular assist device Restricted cubic spline analysis of the relationship between BPRI and AKI progression, adjusted for confounding factors using Model 4. A U-shaped association was observed with a cut-off value of 12.0. Stratified by initial AKI status within the first 24 hours of ICU stay (T0), U-shaped relationships were found in patients without AKI or with AKI stage 2 at T0, while an L-shaped relationship was observed in those with AKI stage 1. A: Whole population; B: The patients without AKI at T0; C. The patients occurred AKI stage 1 at T0; D: The patients occurred AKI stage 2 at T0 Subgroup and sensitivity analysis In stratified analysis, the higher BPRI quantiles had rather lower risk of AKI progression compared to the Q1 groups (all OR < 1). The Q3 group had the lowest risk of AKI progression among patients without AKI within T0, while the Q4 group exhibited the lowest risk among those with AKI stage 1 or 2 (Table S7). However, the RCS analysis revealed a U-shaped association among patients without AKI or with AKI stage 1 at T0, and an L-shaped relationship among those with AKI stage 2 (Fig. 3). The subgroup analysis was conducted after adjusting for confounders using Model 4, which had a lower AIC than Model 3 (Model 3, AIC: 4215; Model 4, AIC: 4209). The results of most subgroups were consistent with the analysis results of the overall population. Interestingly, the protective effect of the Q4 group was sharply attenuated in the subgroup of patients who did not undergo cardiac surgery, were in shock, or had AECHF. Additionally, among subgroups of patients who were male, underwent cardiac surgery, or had a history of CHF, AMI, atrial fibrillation, hypertension, or diabetes, the Q4 group exhibited the lowest risk of AKI progression. However, there was no significant interaction was observed (all P for interaction > 0.05) (Table S8). To test the robustness, we repeated logistic regression analyses and RCS analysis. Most of the result were consisting with the main analysis (Table S9–S14, Fig. S5). The VIF analysis demonstrated no multicollinearity among BPRI, MBP and VIS (all GVIFs < 5 in unadjusted and adjusted models) (Table S15). Following adjustment for MBP, VIS, or both in logistic regression models, the association between and AKI progression remained consistent which indicated this relationship was independent of MBP and VIS (Table S16).Table 3Logistic regression analyses for the incidence of AKI progressionEvents/totalModel 1Model 2Model 3Model 4OR (95% CI)P valueOR (95% CI)P valueOR (95% CI)P valueOR (95% CI)P valueAKI progressionBPRI/0.98 (0.97–0.99) < 0.0010.98 (0.97–0.99) < 0.0010.99 (0.98–1.00)0.0540.99 (0.98–1.00)0.042Q1472/787RefRefRefRefQ2418/7870.76 (0.62–0.92) < 0.0010.76 (0.62–0.93)0.0070.90 (0.73–1.12)0.3600.94 (0.77–1.17)0.594Q3336/7860.50 (0.41–0.61) < 0.0010.49 (0.40–0.60) < 0.0010.61 (0.48–0.76) < 0.0010.64 (0.52–0.79) < 0.001Q4345/7870.52 (0.43–0.64) < 0.0010.51 (0.42–0.62) < 0.0010.64 (0.51–0.81,) < 0.0010.70 (0.56–0.87)0.001P for trends/0.79 (0.74–0.84) < 0.0010.78 (0.73–0.83) < 0.0010.84 (0.78–0.91) < 0.0010.86 (0.81–0.93) < 0.001Model 1: adjusted for none. Model 2: adjusted for gender, age, race, BMI; Model 3: Model2 and adjusted for: hemoglobin, platelets, albumin, creatinine, glucose, PT, APTT, ALT, total bilirubin, lactate, pH, po2, pco2, TNT, CKMB, Hba1c, NT-proBNP, fluid balance, APS, SIRS, blood transfusion, ACEI/ARB, amiodarone, anticoagulants drug, CCB, NSAID, beta blocker, hypolipidemic drug, IABP, MCS; Model 4: Model2 and adjusted for: classification of HF, surgery, hypertension, AMI, valve disorder, AF, cerebrovascular disease, liver disease, cancer, diabetes, lipoprotein metabolism disorders, shock, CKD, gastrointestinal bleeding, acute pancreatitis, sepsis; * BPRI quartile: Q1: 0.01–2.37; Q2: 2.37–4.77; Q3: 4.77–9.37; Q4: 9.37–91.97 Table 3Logistic regression analyses for the incidence of AKI progressionEvents/totalModel 1Model 2Model 3Model 4OR (95% CI)P valueOR (95% CI)P valueOR (95% CI)P valueOR (95% CI)P valueAKI progressionBPRI/0.98 (0.97–0.99) < 0.0010.98 (0.97–0.99) < 0.0010.99 (0.98–1.00)0.0540.99 (0.98–1.00)0.042Q1472/787RefRefRefRefQ2418/7870.76 (0.62–0.92) < 0.0010.76 (0.62–0.93)0.0070.90 (0.73–1.12)0.3600.94 (0.77–1.17)0.594Q3336/7860.50 (0.41–0.61) < 0.0010.49 (0.40–0.60) < 0.0010.61 (0.48–0.76) < 0.0010.64 (0.52–0.79) < 0.001Q4345/7870.52 (0.43–0.64) < 0.0010.51 (0.42–0.62) < 0.0010.64 (0.51–0.81,) < 0.0010.70 (0.56–0.87)0.001P for trends/0.79 (0.74–0.84) < 0.0010.78 (0.73–0.83) < 0.0010.84 (0.78–0.91) < 0.0010.86 (0.81–0.93) < 0.001Model 1: adjusted for none. Model 2: adjusted for gender, age, race, BMI; Model 3: Model2 and adjusted for: hemoglobin, platelets, albumin, creatinine, glucose, PT, APTT, ALT, total bilirubin, lactate, pH, po2, pco2, TNT, CKMB, Hba1c, NT-proBNP, fluid balance, APS, SIRS, blood transfusion, ACEI/ARB, amiodarone, anticoagulants drug, CCB, NSAID, beta blocker, hypolipidemic drug, IABP, MCS; Model 4: Model2 and adjusted for: classification of HF, surgery, hypertension, AMI, valve disorder, AF, cerebrovascular disease, liver disease, cancer, diabetes, lipoprotein metabolism disorders, shock, CKD, gastrointestinal bleeding, acute pancreatitis, sepsis; * BPRI quartile: Q1: 0.01–2.37; Q2: 2.37–4.77; Q3: 4.77–9.37; Q4: 9.37–91.97 Logistic regression analyses for the incidence of AKI progression Model 1: adjusted for none. Model 2: adjusted for gender, age, race, BMI; Model 3: Model2 and adjusted for: hemoglobin, platelets, albumin, creatinine, glucose, PT, APTT, ALT, total bilirubin, lactate, pH, po2, pco2, TNT, CKMB, Hba1c, NT-proBNP, fluid balance, APS, SIRS, blood transfusion, ACEI/ARB, amiodarone, anticoagulants drug, CCB, NSAID, beta blocker, hypolipidemic drug, IABP, MCS; Model 4: Model2 and adjusted for: classification of HF, surgery, hypertension, AMI, valve disorder, AF, cerebrovascular disease, liver disease, cancer, diabetes, lipoprotein metabolism disorders, shock, CKD, gastrointestinal bleeding, acute pancreatitis, sepsis; * BPRI quartile: Q1: 0.01–2.37; Q2: 2.37–4.77; Q3: 4.77–9.37; Q4: 9.37–91.97 ROC curve analysis In ROC curve analysis, BPRI showed limited predictive ability for AKI progression (AUC: 0.580, 95% CI: 0.560–0.599) in overall population. It performed modestly better than MBP (AUC: 0.521, 95% CI: 0.502–0.542; p < 0.001), but showed no significant difference compared with VIS (AUC: 0.575, 95% CI: 0.555–0.594, p = 0.124). When stratified by AKI status within T0, both BPRI and VIS exhibited higher AUCs than in the overall population, except for MBP in patients with AKI stage 1. Among patients without AKI within T0, BPRI (AUC: 0.597, 95% CI: 0.562–0.631) significantly outperformed both MBP (AUC: 0.549, 95% CI: 0.512–0.584, p = 0.027) and VIS (AUC: 0.584, 95% CI: 0.549–0.618, p = 0.019). In patients with AKI stage 2 at T0, BPRI demonstrated modest predictive performance (AUC: 0.639, 95% CI: 0.606–0.670) and significantly outperformed MBP (AUC: 0.547, 95% CI: 0.511–0.581, p < 0.001), but did not differ significantly from VIS (AUC: 0.625, 95% CI: 0.591–0.656, p = 0.080) (Fig. S6, Table S17). Discussion Our findings revealed an asymmetric U-shaped correlation between BPRI and the incidence of AKI progression, with a cut-off value of 12.0. Both elevated and reduced BPRI were related to a higher risk of AKI progression, while the risk of AKI progression changed more rapidly if BPRI below the cut-off value regardless initial AKI situation. Notably, the Q1 group was related to higher risk of AKI progression and had the lowest 90-day survival rate. Known as CRS, the dysfunction of either the heart or the kidneys in acute or chronic settings can initiate and perpetuate vicious cycles that often accelerate the deterioration of both cardiac and renal function [3, 5, 23]. The impairment of cardiac function, along with the treatment aimed at alleviating congestive manifestations, may trigger a subsequent reduction in renal function [5]. In turn fluid overload results in cardiac and renal venous congestion, and electrolyte imbalances as well as acidemia contribute to arrhythmia [24]. Both cardiac and renal dysfunction can accelerate cardiovascular and kidney injury through the activation of neurohormonal, immunological and inflammatory pathways [3, 24]. In this study, potentially due to the fact that HF patients experiencing peripheral hypoperfusion and persistent hypotension were more likely to receive vasoactive drugs in clinical practice, 64.9% (2041/3147) of patients occurred AKI within 24 hours ICU, and 49.9% (1571/3147) experienced AKI progression in the following 48 hours. The incidence of AKI Stage 3, need for RRT, and 90-day mortality were significantly higher in patients with AKI progression compared to those without AKI progression, which supported that the AKI progression in HF is associated with poorer prognoses. Affected by cardiac output (CO), systemic vascular resistance (SVR), and mean systemic pressure, MAP is regarded as the driving force for perfusion in most crucial organs, especially when MAP drops beneath the autoregulation threshold [25]. Vasoactive drugs are often selected based on the patient’s condition to increase perfusion to the vital organs [4], and the dosages of different vasoactive drugs can be standardized by VIS [10]. As the ratio of MAP to VIS, BPRI is used to assess the cardiovascular responsiveness to vasoactive drugs [13]. Chen et al. demonstrated that this novel index exhibited good predictive performance for in-hospital mortality in patients with sepsis. In both the internal and the two external cohorts, all AUROC values were above 0.70, which is comparable to the performance of the SOFA score and the Acute Physiology Score. An L-shaped correlation was detected between BPRI and the in-hospital mortality among sepsis patients [13]. However, to our best knowledge the relationship between BPRI and AKI in HF patients has not been previously reported. In this study, minimal MAP value and maximal VIS in a period were collected to calculate BPRI and the minimum BPRI value within T0 was set as the exposure variable. Therefore, the minimal BPRI may reflect the patient’s most vulnerable hemodynamic state and signal a critical transition during the resuscitation phase of arterial hypotension or shock. Our results demonstrated that BPRI was independently associated with AKI progression in HF patients. The observed asymmetric U-shaped relationship implies a potential therapeutic window for BPRI, which could inform individualized hemodynamic optimization. Additionally, the protective effect of high BPRI was sharply attenuated in the patients who did not undergo cardiac surgery, were in shock, or had AECHF, highlighting the importance of implementing vasoactive drug strategies in these subgroups. While the underlying mechanisms remain unclear, several findings may help to explain. Firstly, impaired cardiovascular responsiveness to catecholamine is common in patients with HF due to adrenergic desensitization [26]. The cardiac function and blood vessels respond not only to exogenous but also to endogenous vasoactive agents [15]. Prolonged activation of the sympathetic nervous system (SNS), which is a key pathophysiological feature of HF and kidney diseases, increases the levels of circulating catecholamines and further leads to adrenoceptor desensitization [26, 27]. Other receptors regulated the vascular tone also undergo desensitization processes during shock stages [27]. In addition, in critically ill HF patients, systemic activation of inflammation, large amounts of vasoactive drugs, hypoxia, acidosis, hyperlactatemia and critical illness-related corticosteroid insufficiency also contribute to hypo-responsiveness to vasopressors [14, 27]. Given the variety of factors that can influence cardiovascular responsiveness to vasoactive drugs, the minimal BPRI may reflect the overall pathophysiological state and vascular functional reserve during HF. Secondly, during acute cardiovascular dysfunction, reduction of cardiovascular response to vasoactive drugs leads to uncorrectable hypotension or even refractory shock [15]. Persistent hypotension is an important driver of organ dysfunction [14], as it results in reduced renal blood flow and renal hypoxia which play a fundamental role in AKI development during HF [23], and contributes to AKI persistence when it occurs [25]. Previous studies have demonstrated that lower minimal MAP is related to AKI incidence in patients with hypotension [28, 29], and higher MAP in the initial 12 hours of AKI stage 1 were significant protective factors for AKI stage 3 [30]. Because of the inconsistent definitions of hypotension and diverse study samples, the meta-analysis failed to establish a connection between hypotension and AKI, diverging from descriptive research results [31]. Nevertheless, a MAP below 55 mmHg was most consistently associated with AKI [31]. The optimal MAP target remains challenging in critically ill patients [32], maintaining MAP at a moderate level could reduce the risk of AKI in HF patients [33]. Maintaining a stable MAP in patients with reduced cardiovascular response is challenging and may require higher doses of vasoactive drugs, which could be associated with more adverse effects. Thirdly, different vasoactive drugs have distinct effects on renal function and perfusion. Most vasoactive drugs can improve renal perfusion in low cardiac output states or severe hypotension [25]. When correcting severe hypotension, norepinephrine and vasopressin can increase the renal function or glomerular filtration but angiotensin may decrease renal function [25]. A meta-analysis found that levosimendan was the safest inotropic option for renal protection in patients with CRS in advanced HF compared to dobutamine and milrinone. However, it also failed to reduce the incidence of AKI [34]. Q1 group had the lowest survival rate regardless of whether AKI progression occurred. Interestingly, compared to the Q3 and Q4 groups, the Q2 group showed lower survival rates when AKI progression occurred, but similar survival rates when AKI progression did not occur. These findings emphasize that AKI progression is a risk factor for short-term mortality in HF and also indicate the prognostic value of BPRI in HF patients, especially when complicated by kidney impairment. Compared to the Q3 and Q4 groups, the Q1 group had higher illness severity scores and more comorbidities while the Q2 group had similar baseline characteristics. This indicated that adverse outcomes may be determined not only by the changes in creatinine levels or urine output, but also by the clinical context in which the kidney function change occur [35]. We also explored the incidences of arrhythmia which are common adverse effect of vasoactive drugs. Interestingly, the incidences of ventricular tachycardia, ventricular fibrillation, and cardiac arrest were low, which seemed inconsistent with the high mortality of this population and could be attributed to the sensitivity of electrocardiogram monitoring. Regarding new-onset AF, the incidence was higher in the Q1 and Q2 groups. Several limitations should be noted. Firstly, this was a single-center retrospective cohort study, so we cannot establish a causal relationship between BPRI and AKI progression despite adjusting for several confounders. Secondly, given the database limitations, we could not evaluate the influence of cardiac function and central venous pressure (CVP) on renal function due to the lack of invasive hemodynamics and echocardiography data, such as cardiac output, CVP and left ventricular ejection fraction (LVEF). Among patients in the coronary care unit, a lower LVEF was associated with a higher risk of acute kidney disease [36]. In post-cardiac surgery patients with HF, HF with mildly reduced ejection fraction (HFmrEF) was associated with a greater risk of moderate to severe AKI than HF with preserved ejection fraction (HFpEF), while the risk did not differ significantly between HF with reduced ejection fraction (HFrEF) and HFpEF [37]. Both HFrEF and HFpEF can result in reduced cardiac output, elevated CVP and activation of neurohormonal and inflammatory pathways, all of which may initiate and perpetuate CRS [3]. The interaction of LVEF and AKI progression was complex. But as previously discussed, MAP may be the primary determinant of renal perfusion in the setting of severe hypotension, while the overall pathophysiological state likely governs cardiovascular responsiveness to vasoactive drugs. Thirdly, we attempted to construct the model of CRS in an acute setting, but this study could not distinguish between the types of CRS due to the frequent overlap among types in clinical practice [3]. Fourthly, noncatecholaminergic agents and MCS have shown massive potential in restoring hemodynamics and reduce the need for catecholamines and have become a trend in critical care these years [26]. Based on the medication characteristics of MIMIC IV v3.0, we chose VIS formal [20] which includes noncatecholaminergic agents (milrinone, vasopressin), but could not evaluate the effect of MCS and new vasoactive drugs, such as levosimendan, methylene blue on the blood pressure. Fifthly, despite consistent findings in sensitivity analyses excluding short-term vasoactive drug users, the minimal BPRI within 24 hours of ICU admission may still be influenced by transient episodes of extreme hypotension or high-dose vasoactive therapy and not reflect sustained exposure or cumulative renal risk. Future research should explore time-dependent hemodynamic indices, including time-weighted average BPRI and cumulative duration of BPRI below a critical threshold, which may more accurately reflect the evolving burden of hypoperfusion and its association with end-organ dysfunction. Sixthly, though the association between BPRI and AKI progression was significantly among HF patients, the predictive ability of BPRI was limited and did not differ significantly from that of VIS in entire cohort. This may reflect the multifactorial nature of CRS, in which a single hemodynamic index is unlikely to fully capture the complex interplay between cardiac dysfunction and kidney injury. Notably, when stratified by AKI situation within T0 both BPRI and VIS showed improved prediction, suggesting their performance could be dependent on clinical situation. Recent studies have shown that BPRI was a strong predictor of in-hospital mortality in patients with septic shock and cardiogenic shock (CS) [13, 38, 39]. Notably, one study in CS patients reported that models incorporating BPRI achieved AUCs exceeding 0.75 [38], while another demonstrated that adding BPRI to conventional scoring systems improved the prediction of hospital mortality [39]. Although a recent meta-analysis linked higher VIS to increased risks of mortality and AKI early among cardiac surgical patients [40], the selection and titration of vasoactive drugs based on assessments of blood pressure and cardiac output, remains largely dependent on clinician judgment. BPRI provides a simple, interpretable measure of blood pressure responsiveness to vasoactive support and can be easily automated within electronic medical record systems. Therefore, the potential predictive value of BPRI for AKI progression in HF patients should be further evaluated in multicenter prospective studies and randomized controlled trials that incorporate a broader set of HF- and AKI-related clinical, hemodynamic, and biomarker variables. Conclusion Among HF patients, AKI progression is associated with poorer prognoses. The correlation between BPRI within the first 24 hours of ICU admission and AKI progression in the following 48 hours is an asymmetric U-shape, with a cut-off value of 12.0. When BPRI is below the cut-off value, lower values were significantly associated with a higher incidence of new-onset AKI or progression to a more severe AKI stage irrespective of the patient’s baseline kidney status. BPRI is a clinically intuitive and easily calculable measure of hemodynamic response to vasoactive therapy. Nevertheless, the utility of BPRI as a practical bedside predictor of AKI progression, particularly when integrated with comprehensive clinical, hemodynamic, and biomarker data, still remains to be confirmed in prospective multicenter trials. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1